Preoperative C-reactive protein as a prognostic and therapeutic marker for colorectal cancer

Journal of Surgical Oncology

Volumn 98, Issue 7, 2008, Pages 540-544

  Koike, Yuhki ^a   Miki, Chikao ^a   Okugawa, Yoshinaga ^a   Yokoe, Takeshi ^a   Toiyama, Yuji ^a   Tanaka, Koji ^a   Inoue, Yasuhiro ^a   Kusunoki, Masato ^a  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Adjuvant chemotherapy; Carcinoembryonic antigen; Stage II patients

Indexed keywords

C REACTIVE PROTEIN; CARCINOEMBRYONIC ANTIGEN; FLUOROURACIL; SERUM ALBUMIN;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; COLORECTAL SURGERY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; FEMALE; HUMAN; HUMAN TISSUE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; C-REACTIVE PROTEIN; CARCINOEMBRYONIC ANTIGEN; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; FEMALE; FLUOROURACIL; HUMANS; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PREOPERATIVE CARE; PROGNOSIS; RETROSPECTIVE STUDIES; SERUM ALBUMIN; TUMOR MARKERS, BIOLOGICAL; WEIGHT LOSS;

EID: 56649111424     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21154     Document Type: Article

References (24)

1. Duffy MJ: Carcinoembryonic antigen as a marker for colorectal cancer: Is it clinically useful? Clin Chem 2001;47:624-630.
2. Compton CC, Fielding LP, Burgart LJ, et al.: Prognostic factors in colorectal cancer. Arch Pathol Lab Med 2000;124:979-994.
3. Moertel CG, Fleming TR, Macdonald JS, et al.: An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA 1993;270:943-947.
4. Greene FL, Page DL, Fleming ID, et al.: editors. AJCC cancer staging manual. (6th edn). New York: Springer; 2002.
5. Duffy MJ, van Dalen A, Haglund C, et al.: Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer 2007;43:1348-1360.
6. Canna K, McMillan DC, McKee RF, et al.: Evaluation of a cumulative prognostic score based on the systemic inflammatory response in patients undergoing potentially curative surgery for colorectal cancer. Br J Cancer 2004;90:1707-1709.
7. Nozoe T, Matsumata T, Kitamura M, et al.: Significance of preoperative elevation in serum C-reactive protein as an indicator for prognosis in colorectal cancer. Am J Surg 1998;176:335-338.
8. McMillan DC, Canna K, McArdle CS: Systemic inflammatory response predicts survival following curative resection for colorectal cancer. Br J Surg 2003;90:215-219.
9. Crozier JE, McKee RF, McArdle CS, et al.: The presence of a systemic inflammatory response predicts poorer survival in patients receiving adjuvant 5-FU chemotherapy following potentially curative resection for colorectal cancer. Br J Cancer 2006;94:1833-1836.
10. McMillan DC, Wotherspoon HA, Fearon KC, et al.: A prospective study of tumor recurrence and the acute-phase response after apparently curative colorectal cancer surgery. Am J Surg 1995;170:319-322.
11. Nozoe T, Matsumata T, Sugimachi K: Preoperative elevation of serum C-reactive protein is related to impaired immunity in patients with colorectal cancer. Am J Clin Oncol 2000;23:263-266.
12. Gunter MJ, Stolzenberg-Solomon R, Cross AJ, et al.: A prospective study of serum C-reactive protein and colorectal cancer risk in men. Cancer Res 2006;66:2483-2487.
13. Jamieson NB, Glen P, McMillan DC, et al.: Systemic inflammatory response predicts outcome in patients undergoing resection for ductal adenocarcinoma head of pancreas. Br J Cancer 2005;92:21-23.
14. Crumley AB, McMillan DC, McKernan M, et al.: An elevated C-reactive protein concentration, prior to surgery, predicts poor cancer-specific survival in patients undergoing resection for gastro-oesophageal cancer. Br J Cancer 2006;94:1568-1571.
15. Elahi MM, McMillan DC, McArdle CS, et al.: Score based on hypoalbuminemia and elevated C-reactive protein predicts survival in patients with advanced gastrointestinal cancer. Nutr Cancer 2004;48:171-173.
16. Forrest LM, McMillan DC, McArdle CS, et al.: Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer. Br J Cancer 2004;90:1704-1706.
17. Al Murri AM, Wilson C, Lannigan A, et al.: Evaluation of the relationship between the systemic inflammatory response and cancer-specific survival in patients with primary operable breast cancer. Br J Cancer 2007;96:891-895.
18. Ramsey S, Lamb GW, Aitchison M, et al.: The longitudinal relationship between circulating concentrations of C-reactive protein, interleukin-6 and interleukin-10 in patients undergoing resection for renal cancer. Br J Cancer 2006;95:1076-1080.
19. Miki C, Konishi N, Ojima E, et al.: C-reactive protein as a prognostic variable that reflects uncontrolled up-regulation of the IL-1-IL-6 network system in colorectal carcinoma. Dig Dis Sci 2004;49:970-976.
20. Kawano M, Hirano T, Matsuda T, et al.: Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 1988;332:83-85.
21. Peterson VC, Baxter KJ, Love SB, et al.: Identification of objective pathological prognostic determinants and models of prognosis in Dukes' B colon cancer. Gut 2002;51:65-69.
22. Al-Shaiba R, McMillan DC, Angerson WJ, et al.: The relationship between hypoalbuminaemia, tumour volume and the systemic inflammatory response in patients with colorectal liver metastases. Br J Cancer 2004;91:205-207.
23. Du Clos TW: Function of C-reactive protein. Ann Med 2000;32:274-278.
24. Kinoshita T, Ito H, Miki C: Serum interleukin-6 level reflects the tumor proliferative activity in patients with colorectal carcinoma. Cancer 1999;85:2526-2531.